Mydecine Innovations Group Announces Extended Lock-Up Arrangement
DENVER, Aug. 25, 2020 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” or the “Company”), today announced that it has engaged with certain shareholders to enter into voluntary lock-up agreements (the “Lock-up Agreements”) applying resale restrictions on up to 52,908,420 common shares (the “Restricted Shares”) extending the period of time before the shares become free trading. The Restricted Shares were issued pursuant to the Company’s non-brokered private placement closed in May 2020, and are set to become free trading upon expiry of the applicable statutory hold period.
The voluntary Lock-up Agreements stipulate that those shareholders will not offer to sell, contract to sell or otherwise dispose of any of the Restricted Shares, or enter into any transaction to such effect, directly or indirectly, in addition to other restrictions, for a period of 120 days following the date that the original resale restriction was to lapse.“The overwhelming response by existing shareholders of the Company to voluntarily lock-up their shares clearly demonstrates the widespread confidence in our long-term strategy,” said Joshua Bartch, CEO of Mydecine. “We have a vision of consistent and sustained growth, and this lock-up arrangement further shows our existing shareholders’ confidence in our ability to execute on that vision and strategy.”About Mydecine Innovations Group Inc.
Mydecine Innovations Group™ is a publicly traded life sciences parent company dedicated to the development and production of adaptive pathway medicine, natural health products and digital health solutions stemming from fungi. Mydecine’s experienced cross functional teams have the dynamic capabilities to oversee all areas of medicine development including synthesis, genetic research, import/export, delivery system development, clinical trial execution, through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and fungtional™ mushroom vitality products. Our portfolio of unified companies, including Mydecine Health Sciences™, Mindleap Health™, and NeuroPharm™ focus on providing innovative and effective options that can provide millions of people with a healthier quality of life.About Mindleap Health Inc.
Mindleap is developing an advanced digital health platform that will provide support for people that are looking to achieve personal transformations and overcome mental health challenges. Mindleap is the only digital health platform that combines telehealth with mood, emotion and habit tracking. This is a paradigm shift to conventional mental health as Mindleap personalized support and users have the tools needed to track their progress and take control of their mental health.For further information about Mydecine Innovations Group Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com.On behalf of the Board of Directors:
Joshua Bartch, Chief Executive Officer
[email protected]Corp Communication:
Charles Lee, Investor Relations
+1 (250) 488-6728Public Relations:
Cynthia Salarizadeh, PR
[email protected]The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward- looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.